Eli Lilly’s aquires AtaiBeckley for $3.8 billion
This is a watershed moment for psychedelic medicine. Eli Lilly’s acquisition of AtaiBeckley for up to $3.8 billion sends a strong signal that psychedelic therapeutics are moving from the margins…
Read the Article